FDANews
FDAnews Device Daily Bulletin

Arch Presents Data for AC5 Topical Hemostatic Device from First Clinical Study

Aug. 16, 2016

Arch Therapeutics said that a recent clinical study shows its AC5 hemostatic device met its primary and secondary endpoints.

The device is designed to control bleeding and fluid loss in order to provide faster and safer surgical and interventional care.

The clinical study consisted of 46 patients, including 10 who were taking antiplatelet monotherapy. — Cynthia Jessup

View today's stories